这场舆论战，爱康不得不赢

Core Viewpoint - The article discusses the controversies surrounding Aikang Guobin, a leading health checkup institution in China, particularly focusing on a case involving a lawyer who was diagnosed with late-stage cancer after years of checkups without any cancer risk being detected. This incident has sparked public outrage and raised questions about the reliability of health checkups and the responsibilities of such institutions [1][2][10]. Company Summary - Aikang Guobin has faced multiple complaints and legal issues, including a lawsuit for contract disputes and fines for inadequate reporting practices [1]. - The company has a history of serving millions of patients over two decades but is now under scrutiny due to a high-profile case that has led to significant public backlash [1][10]. - Aikang has never sued a customer before, indicating a shift in its approach to handling customer complaints and public relations [1][2]. Industry Summary - The health checkup industry is at a critical juncture, transitioning from a focus on scale to quality, with Aikang needing to avoid being labeled as a "missed diagnosis" institution [6][15]. - The market for health checkups in China reached 292.2 billion yuan in 2024, with projections to exceed 371.1 billion yuan in 2025, indicating a growing demand despite recent challenges [15]. - The introduction of AI and advanced diagnostic technologies is seen as essential for improving service quality and maintaining competitiveness in the evolving market [16][18].